Tyra Biosciences (TYRA) Share-based Compensation (2020 - 2026)
Tyra Biosciences (TYRA) posted Share-based Compensation of $74.4 million for Q1 2026, up 875.48% on a QoQ basis from $7.6 million in Q4 2025, and up 1910.81% year-over-year from $3.7 million in Q1 2025.
Tyra Biosciences (TYRA) Share-based Compensation (2020 - 2026) Analysis & Trends
Tyra Biosciences' Share-based Compensation history runs 7 years deep, the most recent figure standing at $74.4 million for Q1 2026.
- Quarterly Share-based Compensation rose 1910.81% year-over-year to $74.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $74.4 million (up 232.35% YoY) and the FY2025 annual result came in at $75.8 million, up 16.44% from the prior year.
- Share-based Compensation was $74.4 million for Q1 2026 at Tyra Biosciences, up from $7.6 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $74.4 million in Q1 2026 and bottomed at $16000.0 in Q4 2022.
- A 5-year average of $9.6 million and a median of $4.4 million in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation tumbled 99.03% — and 2023, when it surged 26062.5%.
- Tyra Biosciences' Share-based Compensation stood at $16000.0 in 2022, then jumped by 26062.5% to $4.2 million in 2023, then soared by 60.11% to $6.7 million in 2024, then increased by 13.8% to $7.6 million in 2025, then soared by 875.48% to $74.4 million in 2026.
- Business Quant data shows TYRA's Share-based Compensation at $74.4 million in Q1 2026, $7.6 million in Q4 2025, and $7.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Tyra Biosciences | 1.90 Bn | 1.90 Bn | - | 74.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 74.40 Mn |
| Mar 31, 2026 | 74.40 Mn |
| Dec 31, 2025 | 7.63 Mn |
| Dec 31, 2025 | 7.63 Mn |
| Sep 30, 2025 | 7.58 Mn |
| Sep 30, 2025 | 7.58 Mn |
| Jun 30, 2025 | 6.38 Mn |
| Jun 30, 2025 | 6.38 Mn |
| Mar 31, 2025 | 3.70 Mn |
| Mar 31, 2025 | 3.70 Mn |
| Dec 31, 2024 | 6.70 Mn |
| Dec 31, 2024 | 6.70 Mn |
| Sep 30, 2024 | 7.57 Mn |
| Sep 30, 2024 | 7.57 Mn |
| Jun 30, 2024 | 4.41 Mn |
| Jun 30, 2024 | 4.41 Mn |
| Mar 31, 2024 | 2.70 Mn |
| Mar 31, 2024 | 2.70 Mn |
| Dec 31, 2023 | 4.19 Mn |
| Dec 31, 2023 | 4.19 Mn |